Naked plasmid DNA (pDNA) [9] [10] [11] and to a lesser extent, in the spleen, kidney, lung and heart. 9 The expression levels critically depended on the injection volume and rate, strongly suggesting that the 'hydrodynamic' pressure plays a key role in the genetic transfer. 
A safe and simple method is desired for in vivo genetic transduction for gene therapy. Transfection with naked plasmid DNA (pDNA) could be an alternative procedure to conventional viral and nonviral vector systems. Wolff 
et al
1 first demonstrated that the skeletal muscle can be transfected by simply injecting naked pDNA, resulting in significant expression of a foreign gene in myofibers. The procedure is being tested in some clinical trials, including genetic treatment of cardiovascular diseases. 2 Naked pDNA transfection was also successful into other organs, such as heart, 3 lung, 4 skin, 5 and liver. 6 More recently, very high transgene expression was achieved in the liver by intravascular delivery of pDNA. Budker et al 7 and Zhang et al 8 administered pDNA into the liver via the portal vein, hepatic vein or the bile duct. Strong expression was demonstrated in the parenchymal cells of the liver. By injecting a large volume of DNA solution into the tail vein of mice, Liu et al and Zhang et al induced extremely strong marker gene expression in the liver, [9] [10] [11] and to a lesser extent, in the spleen, kidney, lung and heart. 9 The expression levels critically depended on the injection volume and rate, strongly suggesting that the 'hydrodynamic' pressure plays a key role in the genetic transfer. The Epstein-Barr virus (EBV)-based plasmid vector carries two genetic elements from EBV, ie the EBNA1 gene and the oriP element. 12 The EBNA1 binds to oriP in a sequence-specific manner and exerts various effects on the oriP-bearing plasmid. In human cells, the plasmid replicates in synchrony with chromosomal DNA, resulting in long-term retention and expression. 12 The EBNA1 gene and oriP have been employed to engineer artificial chromosomes. 13, 14 On the other hand, the EBNA1 also facilitates nuclear localization of the plasmid, 15, 16 binding of plasmid to the nuclear matrix, 17 and transcriptional up-regulation. [18] [19] [20] Collectively, the EBVbased plasmid vector gives not only a prolonged, but also a stronger expression of the transgene. We have applied the EBV-plasmids to various preclinical studies of gene therapy, including those for hereditary, 21 chronic, 22, 23 as well as malignant diseases. [24] [25] [26] [27] In some of these studies, the EBV-based plasmid vectors were combined with cationic liposomes, 25, 28 cationic polymers, 23, [25] [26] [27] 29 electroporation 21 or gene gun, 30 while in the other studies, naked EBV-based plasmid was injected into the cardiac muscle. 22, 29 In the present study, we transferred the naked EBV-based plasmid vectors to the liver through the intravascular route.
EBV-based and conventional plasmid vectors encoding the luciferase or ␤-gal genes as markers ( Figure 1 , upper panels) were constructed and injected intravenously into the tail vein of mice as described. 9 The injection with pG.GL3, a conventional luciferase-expression vector, Figure 1 Plasmids used in this study. The plasmids were constructed as described previously. 37 The pGEG.4 (upper left) is composed of (1) 
) under the control of another CAG promoter; and (4) the ampicillin-resistant gene and the replication origin for E. coli (colE1). The pG.4 carries the CAG promoter, polyA signal, ampicillin-resistant gene and the replication origin for E. coli (upper right). pGEG.␤ and pGEG.GL3 were constructed from pGEG.4 by inserting the full length coding sequence for the E. coli ␤-gal gene (NotINotI fragment from pSV␤ (Clontech, Palo Alto, CA, USA)) and the modified firefly (Photinus pyralis) luciferase gene, GL3 (derived from pGL3 (Promega, Madison, WI, USA)), respectively. Similarly, pG.␤ and pG.GL3 were constructed from pG.4. The pOG.␤ (lower left) and pOG.E (lower middle) were constructed from pGEG.␤ by deleting the CAG-EBNA1 and CAG-␤-gal, respectively. pOG.fE (lower right) was constructed from pOG.E as follows: the unique AccIII site in the EBNA1 coding region was digested and blunt-ended by a fill-in reaction. The resulting fragment was ligated with T4 DNA ligase. All the plasmid DNA was purified using the Endofree Plasmid Purification system (Qiagen, Hilden, Germany).
resulted in very high levels of marker gene expression in the liver at 8 h after the transfection (1.25 × 10 6 pg/mg protein) (Figure 2a ). The expression level declined 4.8-fold during the following 16 h (Figure 2b) . The results are consistent with the earlier reports on the intravascular delivery of conventional plasmid vectors into the liver. 9, 11 Injection with pGEG.GL3 elicited an approximately 1.7-and 7.2-fold higher expression of the luciferase marker gene in comparison with pG.GL3 at 8 and 24 h after injection, respectively. Similar data were also obtained when the E. coli ␤-gal gene was employed as marker gene (Figure 2c ). When right, middle and left lobes of the liver were differentially examined, virtually the same results were obtained in all the lobes (data not shown). As reported by Liu et al 9 and Zhang et al, 10 the expression level correlated with the plasmid dose (data not shown).
Histochemical analysis of the liver was also performed using the ␤-gal gene as a reporter. In the liver transfected with pG.␤ (a conventional plasmid vector encoding ␤-gal), approximately 10-20% of hepatic parenchymal cells stained with X-gal at 24 h after the injection (Figure 3b) , while 70-80% of hepatocytes showed a vivid blue staining in the liver that had been transfected with pGEG.␤ (an EBV-based plasmid vector with a ␤-gal gene expression cassette) (Figure 3a) . The discrepancy became much larger on day 5, when the pGEG.␤-transfected liver still contained a significant proportion of positive cells (30-40%) while the pG.␤-transfected liver had lost the majority of the transgene expression (5-10%) (Figure 3c  and d) . The ␤-gal positive cells were mainly localized in areas surrounding the central vein.
To confirm the contribution of EBNA1 and oriP to the strong marker gene expression, ␤-gal expression plasGene Therapy mids and EBNA1-expression plasmids were constructed and used for co-transfection experiments (Figure 1 , lower panels). Compared with the transfection with pOG.␤ (a ␤-gal expression plasmid with oriP) alone, co-transfection with pOG.␤ and pOG.E (an EBNA1-expression plasmid with oriP) significantly augmented the ␤-gal expression (Figure 4, 4th versus 5th bars) . The augmentation could not be demonstrated when pOG.␤ was co-transfected with pOG.fE that harbors a frame-shift mutation in the EBNA1 coding sequence (Figure 4, 4th versus 6th bars) . In contrast, co-transfection with pOG.E did not significantly elevate the expression of pG.␤ that lacks oriP (Figure 4 , 2nd versus 3rd bars). These results clearly indicate that both the EBNA1 gene and oriP are required for the augmented expression, the former and the latter functioning in trans and in cis, respectively.
Next we examined the time course of the marker gene expression in the liver ( Figure 5 ). When pG.GL3 was transfected, the luciferase expression reached its maximal level at 8 h after the transfection. The expression level fell sharply thereafter. In sharp contrast, in the pGEG.GL3-transfected liver, the highest expression was seen between 8 to 24 h, and the rate of decline was much slower than that in the pG.GL3-transfected liver. On day 35 after the gene transfer, approximately 100-fold difference in expression levels was seen between groups given an injection with either the EBV-based or conventional plasmids. The luciferase expression fell more rapidly than ␤-gal expression, probably because the luciferase protein is less stable than the ␤-gal protein (Figures 2c  versus 5) .
We also investigated the marker gene expression in organs other than the liver. At 8 h after the injection, 
Figure 2 Intravascular delivery of naked EBV-based plasmid vector into the liver. Eight-week-old female Balb/c mice were intravenously injected into the tail vein with 1.6 ml sterile saline containing 10 g of the indicated plasmids (n = 5). The injection was completed within 5 s. Control mice were injected with saline alone (mock). Eight hours (a), 24 h (b), or indicated days (c) after the injection, mice were killed by cervical dislo-

. Twenty-four hours (a and b) or 5 days (c and d) after the transfection, the livers were excised and immediately stained with X-gal staining solution (0.05% (v/v) 5-bromo-4-chloro-3-indolyl-␤-d-galactoside (Xgal) (Nacalai
GL3 and pG.GL3 (Student's t test).
pGEG.GL3 elicited 1.9 to 3.6 times higher luciferase activity than pG.GL3 did in the spleen, kidney and lung (47.1 versus 24.9 pg/mg protein in the spleen, 586.1 versus 162.3 pg/mg protein in the kidney, 75.5 versus 35.4 pg/mg in the lung) ( Figure 6 ). In the heart, both plasmids gave a comparable level of the marker gene expression (57.2 versus 55.1 pg/mg). One to 5 days after the transfection, the injection with pGEG.GL3 resulted in several-to several hundred-fold higher expression of luciferase than pG.GL3-injection in all organs examined, including the heart. By our method, maximum expression of luciferase reached 2 g/mg protein (Figure 2a) , indicating that the 
GL3 (Student's t test).
Gene Therapy transgene product accounted for approximately 0.2% of total liver protein. In other words, as much as 320 g of luciferase was produced per gram of liver at 8 to 24 h after the single injection.
Although an oriP-bearing plasmid does not replicate in rodent cells, 12, 31 we have previously demonstrated that a significantly high expression of a transgene can be achieved in murine and rat cells by using EBV-based plasmid vectors. 29 This may be attributed to EBNA1 functions other than DNA replication, ie nuclear transfer of the plasmid, binding of the plasmid to the nuclear matrix, and transcriptional enhancement. We have recently found that these functions actually work in rodent cells, at least in some in vitro experimental systems (Kishida et al, unpublished observations). Also, Saeki et al, 32 Kaneda et al, 33 and Nishizaki et al 30 have shown that the EBVbased plasmid vector enabled significantly prolonged expression of marker genes in rodent organs that had been transfected by means of HVJ-liposomes 32, 33 or a gene gun. 30 Taking into account the potential application of naked pDNA injection to gene therapy, constant and persistent expression is desired. In case of cytokine gene transfer, for example, a quite high cytokine concentration may cause severe adverse effects, as suggested by clinical trials with recombinant cytokines. The dose of DNA to be administered must be regulated so that the peak expression level does not exceed a physiological level. Rapid decay of expression is disadvantageous, because the expression may drop below an effective concentration at a relatively early time period. In this regard, the EBVbased plasmid vector may be more advantageous than conventional ones.
Although the mechanism of the 'hydrodynamics-based transfer' is not well elucidated, some receptor-mediated process is advocated. 34 The high pressure may increase the permeability of liver fenestra, so that pDNA is recruited to the surface of hepatocytes and taken up by some cell surface receptor(s).
It has not yet been established whether the intravascular administration with naked pDNA could be applicable to clinical use. He et al 35 injected a naked conventional plasmid vector encoding flt3 ligand into the tail vein of mice. They found a drastic increase in vivo in the number of dendritic cells and natural killer cells, 35 indicating that the intravascular transfection of the liver with pDNA is quite useful in obtaining biological effects of some functional gene. Zhang et al 36 reported effectiveness, as well as safety, of genetic transfer into limb muscles of a nonhuman primate through an intra-arterial injection with naked pDNA. On the other hand, we have recently shown that naked EBV-based plasmid DNA was quite effective in transducing cardiac muscle. 22, 29 When an EBV-based plasmid containing the ␤ 2 -adrenergic receptor gene was injected into the myocardium of cardiomyopathic hamsters, a significant elevation in cardiac output was obtained, suggesting a novel gene therapy strategy against heart failure. 22 The 'hydrodynamics-based procedure' may become an attractive approach for gene therapy of various diseases as well as functional, in vivo analysis of genes of interest.
